Suchergebnisse - "Roberto Ravasio"

PubPharm (49)

1

Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion

in: Nature Communications | 2024

von Rani Pallavi | Elena Gatti | Tiphanie Durfort | +21

2

Cost per Number Needed to Treat (NNT) for upadacitinib in the treatment of bio-exposed patients with moderately-severely active ulcerative rectocolitis

in: Global & Regional Health Technology Assessment | 2024

von Flavio Caprioli | Massimo Claudio Fantini | Francesca Marando | +2

3

Economic evaluation of two therapeutic sequences in the first-line treatment of moderate to severe active ulcerative rectocolitis in Italy

in: AboutOpen | 2024

von Patrizio Armeni | Elena Compagnucci | Gionata Fiorino | +8

4

The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study

in: Global & Regional Health Technology Assessment | 2022

von Arianna Bertolani | Roberto Ravasio | Paola Raimondo | +1

5

Treatment management of patients with systemic lupus erythematosus: a delphi consensus analysis

in: Global & Regional Health Technology Assessment | 2022

von Gian Domenico Sebastiani | Marta Mosca | Roberto Ravasio | +3

6

The Economic impact of Enterosgel® in the hospital treatment of diarrhoeal syndromes associated with different disease conditions

in: AboutOpen | 2021

von Roberto Ravasio | Paola Raimondo

7

Cost-effectiveness analysis of caplacizumab in the new standard of care for immune Thrombotic Thrombocytopenic Purpura in Italy

in: Global & Regional Health Technology Assessment | 2021

von Giovanni Di Minno | Roberto Ravasio

8

A Budget Impact Analysis of the VENTANA PD-L1 SP142 Immunohistochemistry Assay Versus the Dako PD-L1 IHC 22C3 Assay in Patients With Advanced or Metastatic Triple-Negative Breast Cancer Treated With Atezolizumab in Combination With Nab-Paclitaxel

in: Farmeconomia: Health Economics and Therapeutic Pathways | 2021

von Cristian Scatena | Roberto Ravasio | Paola Raimondo | +1

9

Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy

in: Global & Regional Health Technology Assessment | 2021

von Roberto Ravasio | Antonio Costanzo | Silvia Antonelli | +2

10

Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

in: Global & Regional Health Technology Assessment | 2021

von Roberto Caporali | Roberto Ravasio | Paola Raimondo | +1

1
2
3
4
5
Nächster »
[5]